Literature DB >> 31697808

Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.

Luzalba Sanoja-Flores1,2,3,4,5, Juan Flores-Montero1,2,3,4,5, Noemi Puig1,4,5,6, Teresa Contreras-Sanfeliciano7, Roberia Pontes8, Alba Corral-Mateos1,2,3,4,5, Omar García-Sánchez1,4,5,6, María Díez-Campelo1,4,5,6, Roberto José Pessoa de Magalhães9, Luis García-Martín10, José María Alonso-Alonso11, Aranzazú García-Mateo12, Carlos Aguilar-Franco13, Jorge Labrador14, Abelardo Barez-García15, Angelo Maiolino9, Bruno Paiva4,16, Jesús San Miguel4,16, Elaine Sobral da Costa8, Marcos González1,4,5,6, María Victoria Mateos1,4,5,6, Brian Durie17, Jacques J M van Dongen18, Alberto Orfao1,2,3,4,5.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31697808      PMCID: PMC6966491          DOI: 10.1182/blood.2019002610

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  23 in total

1.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

2.  Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.

Authors:  Ivana Moor; Vera U Bacher; Barbara Jeker; Behrouz Mansouri Taleghani; Beatrice U Mueller; Peter Keller; Daniel Betticher; Thomas Egger; Urban Novak; Thomas Pabst
Journal:  Bone Marrow Transplant       Date:  2018-06-08       Impact factor: 5.483

3.  Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system.

Authors:  X Bossuyt; A Bogaerts; G Schiettekatte; N Blanckaert
Journal:  Clin Chem       Date:  1998-05       Impact factor: 8.327

Review 4.  Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.

Authors:  Johannes M Waldschmidt; Praveen Anand; Birgit Knoechel; Jens G Lohr
Journal:  Semin Hematol       Date:  2018-03-01       Impact factor: 3.851

5.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

6.  Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.

Authors:  Mark Korthals; Nina Sehnke; Ralf Kronenwett; Thomas Schroeder; Tobias Strapatsas; Guido Kobbe; Rainer Haas; Roland Fenk
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-02       Impact factor: 5.742

Review 7.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

8.  Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation.

Authors:  Rajshekhar Chakraborty; Eli Muchtar; Shaji K Kumar; Dragan Jevremovic; Francis K Buadi; David Dingli; Angela Dispenzieri; Suzanne R Hayman; William J Hogan; Prashant Kapoor; Martha Q Lacy; Nelson Leung; Morie A Gertz
Journal:  Haematologica       Date:  2017-05-04       Impact factor: 9.941

9.  Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Authors:  S Huhn; N Weinhold; J Nickel; M Pritsch; T Hielscher; M Hummel; U Bertsch; B Huegle-Doerr; M Vogel; R Angermund; M Hänel; H J Salwender; K Weisel; J Dürig; M Görner; H Kirchner; N Peter; U Graeven; F Lordick; M Hoffmann; P Reimer; I W Blau; A Jauch; K Dembowsky; T Möhler; P Wuchter; H Goldschmidt
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

10.  Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.

Authors:  Anna Oberle; Anna Brandt; Minna Voigtlaender; Benjamin Thiele; Janina Radloff; Anita Schulenkorf; Malik Alawi; Nuray Akyüz; Manuela März; Christopher T Ford; Artus Krohn-Grimberghe; Mascha Binder
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941

View more
  17 in total

1.  Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.

Authors:  Laura A Evans; Dragan Jevremovic; Bharat Nandakumar; Angela Dispenzieri; Francis K Buadi; David Dingli; Martha Q Lacy; Suzanne R Hayman; Prashant Kapoor; Nelson Leung; Amie Fonder; Miriam Hobbs; Yi Lisa Hwa; Eli Muchtar; Rahma Warsame; Taxiarchis V Kourelis; Ronald Go; Stephen Russell; John A Lust; Yi Lin; Mustaqeem Siddiqui; Robert A Kyle; Morie A Gertz; S Vincent Rajkumar; Shaji K Kumar; Wilson I Gonsalves
Journal:  Am J Hematol       Date:  2020-03-26       Impact factor: 10.047

2.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.

Authors:  Ankit K Dutta; Jean-Baptiste Alberge; Romanos Sklavenitis-Pistofidis; Elizabeth D Lightbody; Gad Getz; Irene M Ghobrial
Journal:  Nat Rev Clin Oncol       Date:  2022-01-11       Impact factor: 65.011

4.  Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.

Authors:  María A Vasco-Mogorrón; José A Campillo; Adela Periago; Valentin Cabañas; Mercedes Berenguer; María C García-Garay; Lourdes Gimeno; María F Soto-Ramírez; María D Martínez-Hernández; Manuel Muro; Alfredo Minguela
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

5.  Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.

Authors:  Renata Bezdekova; Tomas Jelinek; Romana Kralova; Martin Stork; Petra Polackova; Pavla Vsianska; Lucie Brozova; Jiri Jarkovsky; Martina Almasi; Ivanna Boichuk; Zdenka Knechtova; Miroslav Penka; Ludek Pour; Sabina Sevcikova; Roman Hajek; Lucie Rihova
Journal:  Br J Haematol       Date:  2021-09-09       Impact factor: 8.615

Review 6.  Measurable residual disease in multiple myeloma: ready for clinical practice?

Authors:  Leire Burgos; Noemi Puig; Maria-Teresa Cedena; María-Victoria Mateos; Juan José Lahuerta; Bruno Paiva; Jesús F San-Miguel
Journal:  J Hematol Oncol       Date:  2020-06-22       Impact factor: 17.388

7.  Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

Authors:  Benjamin A Derman; Andrew T Stefka; Ken Jiang; Amanda McIver; Tadeusz Kubicki; Jagoda K Jasielec; Andrzej J Jakubowiak
Journal:  Blood Cancer J       Date:  2021-02-05       Impact factor: 11.037

8.  Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse.

Authors:  Binod Dhakal; Shruti Sharma; Mustafa Balcioglu; Svetlana Shchegrova; Meenakshi Malhotra; Bernhard Zimmermann; Paul R Billings; Alexandra Harrington; Himanshu Sethi; Alexey Aleshin; Parameswaran N Hari
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

Review 9.  International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

Authors:  Luciano J Costa; Benjamin A Derman; Susan Bal; Surbhi Sidana; Saurabh Chhabra; Rebecca Silbermann; Jing C Ye; Gordon Cook; Robert F Cornell; Sarah A Holstein; Qian Shi; James Omel; Natalie S Callander; Wee Joo Chng; Vania Hungria; Angelo Maiolino; Edward Stadtmauer; Sergio Giralt; Marcelo Pasquini; Andrzej J Jakubowiak; Gareth J Morgan; Amrita Krishnan; Graham H Jackson; Mohamad Mohty; Maria Victoria Mateos; Meletious A Dimopoulos; Thierry Facon; Andrew Spencer; Jesus San Miguel; Parameswaran Hari; Saad Z Usmani; Salomon Manier; Phillip McCarthy; Shaji Kumar; Francesca Gay; Bruno Paiva
Journal:  Leukemia       Date:  2020-08-11       Impact factor: 11.528

Review 10.  Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.

Authors:  Alessandro Gozzetti; Donatella Raspadori; Francesca Bacchiarri; Anna Sicuranza; Paola Pacelli; Ilaria Ferrigno; Dania Tocci; Monica Bocchia
Journal:  J Pers Med       Date:  2020-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.